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Abstract. Three months since the detection of the first COVID-19 case in Africa, almost all countries of the continent
continued to report lowermorbidity andmortality than theglobal trend, includingEurope andNorthAmerica.We reviewed
the merits of various hypotheses advanced to explain this phenomenon, including low seeding rate, effective mitigation
measures, population that is more youthful, favorable weather, and possible prior exposure to a cross-reactive virus.
Having a youthful population and favorable weather appears compelling, particularly their combined effect; however,
progression of the pandemic in the region and globally may dispel these in the coming months.
INTRODUCTION
COVID-19 is caused by SARS-CoV-2, which was first de-
tected in December 2019 in Hubei Province, China, and de-
clared a public health emergency of international concern on
January30,2020,andaglobal pandemiconMarch11,2020,by
the WHO.1 Unlike recent pandemics, COVID-19 has caused
extremely high morbidity (∼5.27 million cases) and significant
fatalities (case fatality rate [CFR] ∼6.5%) worldwide, with un-
precedented disruption of people’s lifestyles, and unfathomed
devastation of global economies. Of the 5.27 million cases re-
ported in more than 200 countries worldwide byMay 24, 2020,
the Americas accounted for ∼2.42 million with 5.9% fatalities,
Europe ∼ 1.81 million with 9.3% fatalities, Asia ∼ 927,000 with
2.9% fatalities, and Africa ∼ 108,000 with 3.0% fatalities, and
Oceania∼ 8,600 cases with 1.5% fatalities. The first COVID-19
case in Africa was reported in Egypt on February 14, and
3 months later, the epidemic curve in the continent remained
flatter than that in continental Americas, Europe, and Asia
(Figures 1 and 2), and with a lower CFR than the Americas and
Europe but comparable to Asia. By May 24, 2020, Nigeria
(population ∼ 200 million) had reported 7,526 cases and 221
fatalities (2.9%), whereas Kenya (population ∼ 47 million) had
reported1,192 total casesand50 fatalities (4.2%).2Ontheother
hand, the United States (population ∼ 328 million) on its fourth
month of the pandemic had reported 1,622,670 cases and
97,087 fatalities (6.0%), whereas Italy (population ∼ 60 million)
had reported 229,327 cases and 32,735 fatalities (14.1%)
(Figures1and2). ThehigherCFR in Italymaybedue to relatively
high population density (206 persons/km2) of an aging pop-
ulation (median age ∼ 45 years), when compared with either
Nigeria with a comparable population density (212 persons/
km2) but younger population (median age ∼ 18 years), or
the United States with comparable population age (median
age ∼ 38 years) but lower density (36 persons/km2).3
We argue that the low number of cases in Africa may not be
an artifact of poor surveillance and low testing because an
escalating number of COVID-19 cases would be easily de-
tected through reports of pneumonia clusters at local
hospitals, which has not been observed. Whereas it is likely
that COVID-19 surveillance and testing are weaker in Africa
because of limited resources, the high transmissibility of this
virus demonstrated in Asia, Europe, and North America (basic
reproductive number, Ro, of 2–3
4,5) suggests that local
transmission in densely populated cities of Africa such as
Lagos or Nairobi would result in clusters of pneumonia at local
hospitals. A contrary opinion that SARS-CoV-2 transmission
in the continent is comparable to that elsewhere but pro-
gression to severe disease is significantly lower remains le-
gitimate. Many public health experts are surprised that the
CFR in the region hasnot soared, given the highburdenofHIV/
AIDS, tuberculosis, malaria and other infections, and other
underlying conditions such as malnutrition and high pop-
ulation density in the urban informal settlements with poor
hygiene and sanitation (Figure 2). However, it is worth re-
membering that the underlying comorbidities associated with
severe COVID-19 disease are noncommunicable such as di-
abetes and asthma, which are less prevalent in Africa.6–8 The
As of May 24, 2020, the CFR in Africa has remained below the
global average and that of Europe and the United States, de-
spite significantlyweaker health systems. Here, we reviewed the
merits of various hypotheses advanced to explain the relatively
low morbidity and mortality of SARS-CoV-2 in Africa.
HYPOTHESES
The hypotheses we reviewed included low seeding rate,
effective mitigation measures, population that is more
youthful, favorable weather, and possible preexisting immu-
nity due to prior exposure to other coronaviruses. Other hy-
potheses advanced to try to explain the phenomenon have
fallen apart as the pandemic has progressed. Some experts
argue that there were low numbers of SARS-CoV-2 in-
troduced (seeding) into Africa, primarily because of the low
volume of air travel to the region.9Many African countries also
implemented partial or complete travel restrictions, which
further reduced the rate of introduction of imported cases,
thus making it easier to identify and isolate initial cases
and their contacts, and to limit pockets of transmission. Fac-
ing unprecedented collapse in coordinated multilateral re-
sponse, African countries have demonstrated impressive
innovation and resolve in implementing mitigation measures
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to reduce SARS-CoV-2 spread, largely anchored by the
WHO-supported Integrated Disease Surveillance and Re-
sponse (IDSR) structures and lessons learned from the re-
current Ebola epidemics in the continent.10 Nonetheless, we
view the two hypotheses as less compelling to explain this
initial COVID-19 pandemic trajectory in Africa. As observed,
the high transmissibility of SARS-CoV-2 in susceptible pop-
ulations makes it likely that few introductions would be ade-
quate to trigger a full-blown local epidemic.4,5 Importantly,
most of the COVID-19 mitigation measures applied in Africa
have been less stringent when than those applied in Europe
and the United States, in large part because social distancing
and lockdowns were not feasible in many parts of Africa be-
cause of poverty and overreliance on the informal economic
sector for the livelihood most of the people in the continent.11
Africa’s more youthful population, with a median age of < 20
years when compared with Europe and the United States
(median age > 38 years), may have contributed to the low
numbers of severe COVID-19 cases and deaths.3,12 This is a
plausible argument, even though its contribution may be less
because of other pervasive underlying factors such as malnu-
trition, and risky livelihoodandcultural factors brought about by
the characteristics of the informal economic sectors they work
in, as well as overcrowding within urban settlements. A recent
study assessing the impact of population age on COVID-19
fatalities found a standardized mortality ratio, which use age-
specific CFRs, that was 4-fold less in Africa when compared to
Europe andNorthAmerica and > 2-fold lesswhen compared to
Asia and South America.13 Because most young persons in-
fected with SARS-CoV-2 are asymptomatic or have mild
symptoms that can be missed by targeted surveillance and
testing, the contribution of this factor may be better assessed
by conducting well-designed prevalence studies to determine
the extent of SARS-CoV-2 infections in various settings (urban,
peri-urban, and rural) within the continent.
Africa experiences warmer and drier weather in the Decem-
ber to April season, with average day temperatures > 20C in
the entire sub-SaharanAfrica region andmore than 30 of the 46
countries of that region averaging > 25C as shown in Figure 3.
Only countries in the northern region including Tunisia, Algeria,
Egypt, Libya, and Morocco have day temperatures < 20C
(Figure 3). The sub-Saharan African region has little day tem-
perature variation over the 5months period and throughout the
calendar year, decreasing between May and August but still
staying > 20C in most countries.11,14 It is plausible that this
warmer weather is decreasing the transmissibility of SARS-
CoV-2 in Africa, as has been demonstrated with other re-
spiratory viruses such as influenza.15 In the cases of influenza
viruses, the high disease burden in winter and colder seasons
globally is associated with the increased viability of the virus in
FIGURE 1. COVID-19 epi curves for the United States and Italy (top) and Nigeria and Kenya (bottom). The x axis starts from 2weeks after the first
reported case in the United States (top) and Nigeria (bottom). The different y axis scales were used to allow visibility of the low number of cases in
Nigeria and Kenya when compared with the United States and Italy. Data used to develop these curves were obtained from publicly available
repositories and national health ministries as described in the Data Sources section.
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FIGURE 2. COVID-19 case fatality rate (CFR) for the United States, Italy, Nigeria, and Kenya. Data used to calculate the CFR were downloaded
frompublicly available repositories and national healthministries as described in theDataSources section. The limitations to theCFRprovidedhere
include the fact that the number of cases (denominator) from each country is dependent on the strength of each country’s surveillance system and
may underestimate the actual number of cases because of limitations in testing or those that do not seekmedical care due to asymptomatic ormild
infections.
FIGURE 3. Average daily temperature between December and April over 10 years (2004–2013) in African countries. Data fromCoˆte d’Ivoire were
not available.
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cold dry conditionswith low levels of sunlight and the tendency
of people to spend more time indoors, enhancing spread.10,11
Even in equatorial African countries that do not have prolonged
seasons with extreme temperatures, influenza cases increase
during thecool drymonths.15–17 It is important tonote that other
aerosol-transmitted viruses that emerged in the recent past,
including SARS-CoV-1 in 2002, highly pathogenic H5N1 in-
fluenza virus in 2005, and Middle East respiratory syndrome
coronavirus(MERS-CoV) in 2012, caused few cases in
Africa.18–20 In fact, our ongoing studies on the MERS-CoV, a
virus that has continued to cause smaller human outbreaks in
more than 27 countries globally, have detected widespread
virus transmission in African dromedary camels, the natural
reservoir of the virus, but few acute human cases in Kenya and
the region (I. Ngere and M. K. Njenga, unpublished data).21 A
possible exception to this was the 2009 pandemic H1N1 in-
fluenza virus, which spread rapidly globally including Africa to
establish chronic infections and become part of seasonal in-
fluenzaviruses.22A recent regressionanalysisstudycomparing
effect of temperature on the number ofCOVID-19 cases across
the 204 affected countries, exclusive of other possible factors,
found countries with higher temperatures reporting lower in-
fections, while those with lower temperatures serving as pan-
demic hotspots.23 Other studies on the effect of weather on
SARS-CoV-2 transmission are conflicting. Whereas a field
study in Spain found no evidence of reduction in cases during
different daily temperature fluctuations, laboratory studies
showed low stability of the virus in the environment with titers
declining rapidly at temperatures of 23–25C.24–27
Progression of the pandemic in India, Australia, and New
Zealand supports the argument that warmer weather plays a
positive role in reducing SARS-CoV-2 transmission and dis-
ease severity. India, the world’s second most populous
country (population ∼ 1.38 billion, density 464/km2) with av-
erage daytime temperature > 24C between December and
April, is inhabitedby a slightly younger population (median age
∼ 29 years). The country reported its first case on January 30,
2020 and byMay 22, 2020; it had reported 119,574 cases and
3,600 fatalities (3.0%). Australia (population ∼ 25 million,
density 9/km2) and New Zealand (population ∼ 5 million,
density 18/km2), both inhabited by older populations (median
age ∼ 38 years), had reported 7,095 cases with 101 fatalities
(1.4%) and 1,504 cases with 21 fatalities (1.4%), respectively.
By contrast, Brazil (population 209 mill, density 25/km2) has
warm December to April season, but it had high transmission
rate and fatalities, reporting 312,074 COVID-19 cases and
20,112 (6.4%) fatalities by May 22, 2020, the highest in South
America perhaps because it has struggled to implement
standard mitigation measures to reduce transmission.
The last hypothesis is that a population across Africa has
some level of SARS-CoV-2 immunity because of prior expo-
sure to other coronaviruses. As with SARS-COV-2, a spillover
of zoonotic coronaviruses into thehumanpopulationhasbeen
recorded several times before, and mounting evidence sug-
gests that other strains closely related to human coronavi-
ruses are circulating within bat populations in Africa and
elsewhere.28–32 Although a novel outbreak of coronavirus has
not been reported in the region, the continuous contact be-
tween bats, livestock, and humans in rural Africa may have
resulted in exposure to these emergent coronaviruses and
development of humoral cross-reactivity.21 Antibodies that
target conserved epitopes across virus families have been
identified in humans, as shown for filoviruses where identifica-
tion of antibodies that cross-neutralize multiple Ebolaviruses
resulted in the development of promising pan-Ebolavirus ther-
apeutic antibodies.33–35 The coronavirus spike protein that
mediates cell entry is a target of neutralizing antibodies, and the
SARS-COV-2 spike protein demonstrates 85% nucleotide
homology to a previously identified bat SARS-like coronavirus
and 76% homology to SARS-COV-1.36–38 Antibodies mediate
antiviral activity through both Fab-mediated neutralization and
recruitment of innate immune cells via the antibody Fc domain,
and emerging data indicate that antibodies developed against
SARS-CoV-1 can cross-neutralize SARS-CoV-2.39–43 Such
coronavirus cross-reactive antibodies may contribute to a low
transmission rate and severe disease associated with SARS-
CoV-2 through cross-neutralization and rapid clearance by
Fc-mediated innate immune effector functions. In addition,
a recent study in the United States detected SARS-CoV-2-
reactive CD4+ T cells in up to 60%of SARS-CoV-2 unexposed
persons (collected prior to 2019), suggesting pre-existing cross-
reactivity with other circulating coronaviruses, which evidently
has not be as effective in reducing SARS-CoV-2 transmission
given the high transmission in the country.44 A comprehensive
characterization of humoral and cellular reactivity across coro-
naviruses in the region may not only provide insight into the
COVID-19 trajectory in Africa but also contribute to the ongoing
debate on the role and duration of protective immunity against
SARS-CoV-2.
Finally, a combination of these factors is likely to contribute
even more to the low transmission and reduced disease se-
verity in Africa. In particular, the contrasting trends of the
pandemic in countries presented here, and recent studies
cited, make the combined effects of warmer weather and
youthful population a compelling explanation of the low
COVID-19 disease transmission and severity in Africa. The
presence of preexisting immunity due to prior exposure to
cross-reacting coronaviruses is intriguing but requires further
studies. The WHO has warned that Africa could still see in-
creased cases and deaths, as demonstrated in Brazil, in the
comingmonths, aprogression thatmaydispel thehypotheses
we deem compelling.
DATA SOURCES
Data on the current number of cases in each continent were
obtained from the Europe CDC (https://www.ecdc.europa.eu/en/
geographical-distribution-2019-ncov-cases). Data used to de-
velop the COVID-19 epi curves were accessed from publicly
available repositories and national health ministries. The cumula-
tive cases and fatalities for Kenya were extracted from the situa-
tion reports (SITREPS)byEmergencyOperationCentersunder the
Ministry of Health (www.health.go.ke), whereas those for Nigeria
were extracted from the Nigerian Center for Disease Control
website (https://covid19.ncdc.gov.ng). The United States’ daily
cases were extracted from the CDC (www.cdc.gov), whereas
those for Italy were curated from an interactive web-based dash-
board that tracks COVID-19 in real time developed by the John
Hopkins University of Medicine.(https://coronavirus.jhu.edu/
map.html)45 All confirmed cases include presumptive positive
cases and probable cases, in accordance with CDC guidelines.
The fatality data used to calculate CFRs were downloaded from
https://ourworldindata.org/covid-deaths. To confirm reliability of
these datasets, we cross-checked with the WHO SITREPS
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(WHO, 2020) and www.worldometers.info. Temperature data
were sourced from publicly available online datasets from
Berkeley Earth, covering the months of December to April for
10 years between 2004 and 2013 and averaged by country
(https://stat.world/biportal/). A choroplethmapwasgenerated
inR to show theextracted temperature values for eachcountry
covering this period.
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